Publications by authors named "Tomoyuki Kii"
Background/aim: The therapeutic efficacy of the paclitaxel (PTX) + cetuximab (Cmab) combination regimen was investigated in patients with recurrence or metastasis after superselective intraarterial chemoradiotherapy (SSIACRT) for oral cancer, and the safety was retrospectively examined.
Patients And Methods: All enrolled patients with advanced oral cancer or who had refused surgery over 10 years from December 2012 to December 2022 underwent SSIACRT for 6 to 9 weeks [cisplatin (CDDP): total 160-630 mg/m and radiotherapy: total 50-70 Gy]. Nine cases (tongue cancer, maxillary gingival cancer, and mandibular gingival cancer; three cases each) were subjected to PTX + Cmab therapy.
Superselective intra-arterial chemoradiotherapy (SSIACRT) is one of the curative treatments for advanced oral cancer. SSIACRT can reportedly treat cervical lymph node metastases in the level I-IIA area by super selectively catheterizing the facial artery (FA) and infusing drugs. However, since advanced oral cancer lesions involve a number of feeding vessels, retrograde treatment requires the placement of catheters from the superficial temporal artery (STA) and occipital artery (OA).
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the effects of paclitaxel plus cetuximab, a common treatment for recurrent/metastatic oral squamous cell carcinoma (OSCC), focusing on the changes in NF-κB expression after treatment.
- Eight OSCC cell lines were examined in a 3D culture setup, revealing a significant reduction in NF-κB expression in sensitive cell lines, while resistant ones showed an increase.
- The addition of bortezomib, a proteasome inhibitor, enhanced the effectiveness of the drug combination in resistant cell lines, suggesting a potential strategy to overcome treatment resistance.
Article Synopsis
- This study examines whether local low-dose administration of anti-PD-1 antibody can provide similar antitumor effects and overall survival rates as systemic high-dose administration in treating oral cancer.
- The research involved using a specific cancer cell line in mice and comparing the effects of local and systemic drug delivery on tumor shrinkage and immune markers.
- Results indicated that local low-dose treatment achieved comparable effectiveness to systemic high-dose treatment and may minimize side effects and costs associated with immunotherapy in oral cancer.
Background/aim: The mechanisms through which cetuximab (cMab) coadministration with paclitaxel (PTX) enhances antitumor efficacy remain unclear. We examined the mechanism of the antitumor enhancing effect of cMab by determining changes in gene expression in the PI3K-AKT pathway.
Materials And Methods: Eight human oral squamous cell carcinoma (OSCC) cell lines were cultured three-dimensionally and exposed to PTX + cMab.
Objective: A combination of the taxane anticancer drug paclitaxel (PTX) and molecular target drug cetuximab (cMab) is effective for the treatment of head and neck squamous cell carcinoma (HNSCC). However, its use is associated with serious side effects, such as neuropathy and myelosuppression. In addition, it is administered regardless of patient sensitivity because biomarkers indicating its efficacy are unavailable.
View Article and Find Full Text PDF